1H FY26 Results Presentation
| Stock | Genetic Signatures Ltd (GSS.ASX) |
|---|---|
| Release Time | 26 Feb 2026, 8:20 a.m. |
| Price Sensitive | Yes |
1H FY26 Results Presentation
- Steady sales in Australia, growth in USA & UK
- Gross profit margin declined due to cost increases
- Underlying operating loss improved due to cost savings
- Cash position managed to enable targeted investment
Genetic Signatures Ltd (GSS.ASX) reported its 1H FY26 results, with total revenue of $8.7m, up 2.4% from the prior corresponding period (pcp). This was driven by steady sales in Australia and growth in the USA and UK markets. Gross profit was $4.8m, down 4.0% from pcp, with gross profit margin declining to 55.7% from 58.8% in the pcp due to increases in consumables and raw material costs, mainly relating to respiratory test kits. The company's underlying net loss before tax improved to $6.4m, compared to a loss of $8.4m in the pcp, due to cost savings of $0.6m and a larger R&D tax incentive income of $1.6m. Cash and cash equivalents stood at $29.9m, down $1.4m from 30 June 2025, with cash used in operations of $5.2m and $0.6m on capital expenditure, partially offset by $4.4m received for R&D incentive grants. Looking ahead, the company is focused on increasing awareness of its 3base technology, developing new products and automation, and driving continued growth in the US and EMEA markets to become a more diversified business. The company is also undertaking a detailed review to appropriately reduce operating costs, while supporting innovation across assay development, workflow optimization, instrumentation, and software enhancements.
The company is focused on the following for 2H FY26: - Increasing awareness of 3base technology and continuing to build out customer base with existing products - Identifying and developing new products and automation to address commercial needs - Expecting Australia to remain steady, while focusing on continued growth in the US and EMEA - Detailed review underway to appropriately reduce operating costs, with savings being realized over FY27 - Reviewing options available to deliver shareholder value, with cash position to be managed to enable targeted investment in commercial initiatives and support innovation.